Investors Raise Alarm as Pomerantz Law Firm Investigates EyePoint, Inc. for Potential Securities Fraud

Investor Alert: EyePoint, Inc. Under Scrutiny by Pomerantz LLP

Recent developments surrounding EyePoint, Inc. (NASDAQ: EYPT) have raised significant concerns among investors, prompting the well-respected law firm Pomerantz LLP to initiate an investigation into possible securities fraud. This investigative move follows EyePoint's unfortunate announcement regarding disappointing results from the pivotal Phase 3 clinical trial for its product DURAVYU™, aimed at treating wet age-related macular degeneration (wet AMD).

On August 17, 2026, EyePoint released details revealing that their clinical trial results did not meet the anticipated benchmarks when compared to the established treatment Eylea (aflibercept) by Regeneron Pharmaceuticals. This lack of efficacy was a significant blow, resulting in a staggering 66.98% drop in EyePoint's stock price, which fell from around $14.75 to $4.87 per share in a single day. Such volatility has alarmed many investors who are now questioning the company's transparency and obligations to its shareholders.

Pomerantz LLP is reaching out to EyePoint investors for potential claims related to this incident. The firm has a longstanding reputation in the field of class-action litigations, particularly concerning securities fraud. Founded by Abraham L. Pomerantz, a pioneer in the realm of securities class actions, the firm has been on the front line for over 85 years, advocating for the rights of those adversely affected by corporate malpractice.

Investors are encouraged to contact Danielle Peyton at Pomerantz LLP to explore their legal options regarding this troubling situation. The firm's investigative focus will likely include scrutiny of EyePoint's disclosures and the actions of its officers and directors during the clinical trial phase, assessing whether any unlawful practices occurred.

EyePoint’s management’s response to the results and how they communicated this to their investors will be crucial in determining the next steps. The firm’s previous attempts to generate positive perceptions about DURAVYU™ were clearly undermined by the recent clinical trial findings, leading to increased skepticism about future performance and profitability.

Additionally, as the investigation progresses, both the regulatory implications for EyePoint and the potential repercussions for investors could unfold. If evidence of wrongdoing is found, it could lead to significant repercussions for the involved executives and offer a pathway for investors to recover their losses.

As EyePoint navigates through this turbulent time, stakeholders must remain vigilant and informed about both the legal landscape and the ongoing developments related to the company. Engaging with legal experts who specialize in securities law may provide additional insights and avenues for recourse during this tumultuous period.

The current situation surrounding EyePoint serves as a stark reminder of the inherent risks involved in investing, particularly in the biotech and pharmaceutical sectors, where trial results can significantly impact stock value. Investors should stay tuned for further developments as they evaluate the implications of the investigation by Pomerantz LLP and EyePoint, Inc.'s ongoing performance in the market.